Director’s Council of Public Representatives (COPR)
NIH Public Bulletin – October 2010
Inhaled Nitric Oxide Therapy for Premature Infants Conference
When: October 27–29, 2010
Where: NIH Campus, Natcher Conference Center, Building 45, Bethesda, MD
Institute: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Babies born before the 28th week of pregnancy—more than 30,000 per year in the United States—are particularly vulnerable to breathing problems due to their underdeveloped lungs. Nitric oxide is sometimes used to treat infants with severe breathing problems, and inhaled nitric oxide therapy was approved by the U.S. Food and Drug Administration in 2000 to treat term and near-term infants (born after the 33rd week of pregnancy) with respiratory failure. Since its approval, researchers have examined expanding the use of inhaled nitric oxide therapy to treat premature babies born in or before the 33rd week of pregnancy.
In October, NIH will convene a Consensus Development Conference to assess the available scientific evidence related to the benefits and risks of inhaled nitric oxide therapy for premature infants. The Inhaled Nitric Oxide Therapy for Premature Infants conference will feature experts from across the United States, who will consider various aspects of therapy. The agenda is designed to facilitate productive discussion between speakers and attendees. The three-day conference will conclude with a presentation of a draft consensus statement.
The Inhaled Nitric Oxide Therapy for Premature Infants conference is free and open to the public. You can find more information, including an agenda, and register to attend the conference at http://consensus.nih.gov/2010/ino.htm. If you are unable to attend, you can register to view the conference via webcast, submit online comments regarding the panel's draft statement, and pre-order a final conference statement. For more information, e-mail firstname.lastname@example.org, call (888) 644-2667, or write to "Inhaled Nitric Oxide Therapy for Premature Infants," NIH Consensus Development Program Information Center, P.O. Box 2577, Kensington, MD 20891.